Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biogena Group Invest AGWBO:BIO 60 Receivables Turnover is 0.00 as of Jan. 2026. GuruFocus rates WBO:BIO with a GF Score™ of 60/100 and a GF Value™ of €3.51 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,943 Consumer Packaged Goods companies, Biogena Group Invest AG ranks better than 96.65% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biogena Group Invest AG's Revenue for the
six
months ended in Jan. 2026 was €0.35 Mil. Biogena Group Invest AG's average Accounts Receivable for the
six
months ended in Jan. 2026 was €0.00 Mil.
Biogena Group Invest AG (WBO:BIO) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Biogena Group Invest AG Receivables Turnover Related Terms
Biogena Group Invest AG Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Biogena Group Invest AG's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogena Group Invest AG Receivables Turnover Chart
WBO:BIO vs KHC, GIS, HRL: Receivables Turnover Comparison
For the Packaged Foods subindustry, Biogena Group Invest AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogena Group Invest AG Receivables Turnover vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Biogena Group Invest AG's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Biogena Group Invest AG's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogena Group Invest AG (WBO:BIO) has a Receivables Turnover of 0.00 as of Jan. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biogena Group Invest AG and its competitors. According to the industry distribution chart, Biogena Group Invest AG ranks #65 out of 1943 companies in the Consumer Packaged Goods industry, placing it in the top 3.3%.
Is Biogena Group Invest AG's Receivables Turnover too high?
Biogena Group Invest AG's current Receivables Turnover is 0.00. Based on the distribution chart, Biogena Group Invest AG ranks #65 out of 1943 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Biogena Group Invest AG has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's Receivables Turnover compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Biogena Group Invest AG ranks #65 out of 1943 companies for Receivables Turnover. This places Biogena Group Invest AG in the top 3% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 9.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Consumer Packaged Goods company?
The median Receivables Turnover among Consumer Packaged Goods companies is 9.38, based on 1,943 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biogena Group Invest AG and its competitors. For the Consumer Packaged Goods industry, the median Receivables Turnover is 9.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogena Group Invest AG's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.51, compared to a current price of €4.98 — trading 41.9% above its estimated fair value. The current Receivables Turnover is 0.00. Biogena Group Invest AG's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current Receivables Turnover is 0.00 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued.
The current stock price of €4.98 is trading 41.9% above its estimated GF Value™ of €3.51.
GuruFocus considers Biogena Group Invest AG to be Significantly Overvalued.
Key valuation signals for WBO:BIO:
Receivables Turnover: 0.00
GF Value™: €3.51 vs. price of €4.98 (41.9% above fair value)
No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
60GF Score
Get the complete analysis for WBO:BIO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:BIO has been successfully added to your 
